Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Eleos Unveils Polaris AI Model for Post-Acute Care
Eleos, the leader in AI for post-acute care, announced the launch of Polaris AI, built in collaboration with Google Cloud technology. Polaris AI is enabled by Google Cloud’s family of multimodal models and built on its secure, scalable infrastructure, combined with Eleos’ purpose-built dataset spanning millions of real-world behavioral health sessions. Eleos is delivering one of the most advanced foundational AI models designed for the unique demands of post-acute care, from rising clinician burnout to intensifying regulatory scrutiny across behavioral health, substance use disorder (SUD), home health and hospice care.
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries.
Elektra Health and Oscar Launch HelloMeno Menopause Plan
Elektra Health, a top virtual menopause care provider, and Oscar Health, Inc, a leading healthcare technology company, announced a groundbreaking partnership offering the first-ever menopause health plan, HelloMeno, in the ACA marketplace.
Spring Health Launches VERA-MH for AI Validation in Mental Health
In partnership with a coalition of leaders across healthcare, technology, and ethics, Spring Health announced the release of VERA-MH , the first open-source, clinically grounded evaluation for assessing the safety and effectiveness of AI chatbots used in mental health care. VERA-MH establishes a transparent, evidence-based standard to determine whether chatbots and large language models (LLMs) that offer psychological support meet stringent clinical safety standards.
XTANDI Plus Leuprolide Cuts Death Risk 40% in Prostate Cancer
Pfizer Inc. and Astellas Pharma U.S. Inc. revealed final overall survival results from the Phase 3 EMBARK trial studying XTANDI, in combination with leuprolide and as monotherapy, in men with non‑metastatic hormone‑sensitive prostate cancer with high‑risk biochemical recurrence (BCR). The study found that XTANDI plus leuprolide reduced the risk of death by 40.3% compared with leuprolide alone (Hazard Ratio [HR]: 0.597; 95% Confidence Interval [CI]: 0.444‑0.804; p = 0.0006). This makes it the first androgen receptor inhibitor‑based regimen to show an overall survival benefit in this patient population. Eight‑year overall survival was 78.9% (95% CI: 73.9%–83.1%) in the XTANDI plus leuprolide group versus 69.5% (95% CI: 64.0%–74.3%) in the leuprolide alone group. A numerical improvement in overall survival for XTANDI monotherapy versus leuprolide alone (HR: 0.83; 95% CI: 0.63‑1.095; p = 0.1867) did not reach statistical significance.
To share your insights, please write to us at sudipto@intentamplify.com
